Loss of mitochondrial Ca response and CaMKII/ERK activation by LRRK2 mutation correlate with impaired depolarization-induced mitophagy.

Publication date: Oct 10, 2024

Type	Source	Name
pathway	REACTOME	Mitophagy
drug	DRUGBANK	Calcium
disease	MESH	Parkinson’s disease
drug	DRUGBANK	L-Leucine
disease	MESH	mitochondrial dysfunction
drug	DRUGBANK	Tretamine
drug	DRUGBANK	ATP
disease	MESH	defects
pathway	REACTOME	Reproduction
pathway	REACTOME	Autophagy
drug	DRUGBANK	Calcium cation
drug	DRUGBANK	Streptomycin
pathway	KEGG	Parkinson disease
drug	DRUGBANK	Amino acids
drug	DRUGBANK	Rotenone
drug	DRUGBANK	Trestolone
drug	DRUGBANK	Rifampicin
drug	DRUGBANK	Dacarbazine
drug	DRUGBANK	Dimethyl sulfoxide
drug	DRUGBANK	Chloride ion
drug	DRUGBANK	Magnesium chloride
drug	DRUGBANK	Sucrose
drug	DRUGBANK	Ethanol
drug	DRUGBANK	Cysteamine
drug	DRUGBANK	Oxygen
drug	DRUGBANK	Flunarizine
drug	DRUGBANK	Dextrose unspecified form
drug	DRUGBANK	L-Glutamine
drug	DRUGBANK	Sodium lauryl sulfate
drug	DRUGBANK	Aspartame
drug	DRUGBANK	Albendazole
drug	DRUGBANK	Puromycin
drug	DRUGBANK	Proline
drug	DRUGBANK	Hydrogen peroxide
disease	MESH	oxidative stress
drug	DRUGBANK	Hyaluronic acid
disease	MESH	pathogenesis
drug	DRUGBANK	Isoxaflutole
pathway	KEGG	Oxidative phosphorylation
disease	MESH	synucleinopathies
disease	MESH	death
drug	DRUGBANK	Etoperidone
pathway	REACTOME	Metabolism
drug	DRUGBANK	Dopamine
disease	MESH	tumor
pathway	REACTOME	Apoptosis
disease	MESH	neurodegenerative diseases
pathway	REACTOME	Neurodegenerative Diseases
pathway	REACTOME	Chaperone Mediated Autophagy
pathway	REACTOME	MAP kinase activation
drug	DRUGBANK	Rasagiline
drug	DRUGBANK	Norepinephrine
disease	MESH	Neuroinflammation
disease	MESH	Starvation
disease	MESH	Cardiac diseases
drug	DRUGBANK	L-Tyrosine
drug	DRUGBANK	(S)-Des-Me-Ampa

(Visited 2 times, 1 visits today)

The next generation in scientific exploration and research